Precigen's PAPZIMEOS Receives Full FDA Approval for RRP Treatment

Precigen has announced that the FDA has approved PAPZIMEOS, a non-replicating adenoviral vector-based immunotherapy, for the treatment of adults with recurrent respiratory papillomatosis (RRP). PAPZIMEOS is the first and only FDA-approved therapy for the treatment of adults with RRP. RRP is a rare, debilitating, and potentially life-threatening disease caused by chronic HPV 6 or HPV 11 infection.